Anticoagulant Therapy in COVID-19 Associated Venous Thromboembolism: A Pivotal Risk Factor

Abstract

Get full access to this article

View all access options for this article.

References

Soudet

Basille

Carette

Mercier

Andrejak

Sevestre

. Cardiovascular and venous thromboembolic events after hospital discharge for COVID-19: a prospective single center study [published online ahead of print, 2023 Aug 19]. Angiology. 2024;75:893-898.

Kow

Ramachandram

Hasan

. The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother. 2022;28(2):257-65.

Bradbury

McQuilten

. Anticoagulation in COVID-19. Lancet. 2022;399(10319):5-7.

Ramacciotti

Barile Agati

Calderaro

, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50-9.

Wang

Wahed

Morris

Kreuziger

, et al. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med. 2023;176(4):515-23.